GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (CHIX:PHARMa) » Definitions » Notes Receivable
中文

Pharming Group (CHIX:PHARMA) Notes Receivable

: €0.0 Mil (As of Dec. 2023)
View and export this data going back to 2008. Start your Free Trial

Pharming Group's Notes Receivable for the quarter that ended in Dec. 2023 was €0.0 Mil.


Pharming Group Notes Receivable Historical Data

The historical data trend for Pharming Group's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharming Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharming Group Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Pharming Group Notes Receivable Related Terms

Thank you for viewing the detailed overview of Pharming Group's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group (CHIX:PHARMA) Business Description

Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on developing and producing human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. The revenue is generated from the United States.

Pharming Group (CHIX:PHARMA) Headlines

No Headlines